A randomized controlled trial of the efficacy and safety of twice-daily saxagliptin plus metformin combination therapy in patients with type 2 diabetes and inadequate glycemic control on metformin monotherapy

BMC Endocrine Disorders

Robert Frederich³  Jia Li³  Patricia Buchanan²  Judith L White¹ 

[1] Holston Medical Group, 105 W. Stone Drive, 37660 Kingsport, TN, USA;Willamette Valley Clinical Studies, Eugene, OR, USA;Bristol-Myers Squibb, Lawrenceville, NJ, USA

关键词: Twice-daily;    Hypoglycemia;    Glycemic control;    Diabetes;    Combination therapy;    Metformin;    Saxagliptin;    Dipeptidyl peptidase-4 inhibitor;    Incretin;   

Others  :  864957
DOI  :  10.1186/1472-6823-14-17

 received in 2013-05-08, accepted in 2013-10-29,  发布年份 2014

【 摘 要 】

Background

To compare the safety and efficacy of saxagliptin 2.5 mg twice daily (BID) versus placebo add-on therapy to metformin immediate release (IR) in patients with type 2 diabetes and inadequate glycemic control with metformin alone.

Methods

This multicenter, 12-week, double-blind, parallel-group trial enrolled adult outpatients with type 2 diabetes (glycated hemoglobin [HbA_1c] 7.0%–10.0%) on stable metformin IR monotherapy (≥1500 mg, BID for ≥8 weeks). Patients were randomized to double-blind saxagliptin 2.5 mg BID or placebo added on to metformin IR following a 2-week, single-blind, placebo add-on therapy lead-in period. The primary end point was the change from baseline to week 12 in HbA_1c. Key secondary end points included change from baseline to week 12 in fasting plasma glucose (FPG) and the proportion of patients achieving HbA_1c <7.0% or HbA_1c ≤ 6.5% at week 12. Efficacy was analyzed in all patients who received randomized study drug with ≥1 postbaseline assessment. Safety was assessed in all treated patients.

Results

In total, 74 patients were randomized to double-blind saxagliptin add-on therapy and 86 to placebo add-on therapy. At week 12, least-squares mean changes (95% CI) from baseline HbA_1c (adjusted for baseline HbA_1c) were significantly greater (P = 0.006) in the saxagliptin + metformin group -0.56% (-0.74% to -0.38%) versus the placebo + metformin group -0.22% (-0.39% to -0.06%). Adjusted mean changes from baseline in FPG were numerically greater with saxagliptin versus placebo; the difference (95% CI) -9.5 mg/dL (-21.7 to 2.7) was not statistically significant (P = 0.12). A numerically greater proportion of patients in the saxagliptin group than the placebo group achieved HbA_1c < 7.0% (37.5% vs 24.2%) or HbA_1c ≤6.5% (24.6% vs 10.7%). There were no unexpected safety findings. Hypoglycemia occurred in 4 patients (5.4%) in the saxagliptin group and 1 patient (1.2%) in the placebo group; confirmed hypoglycemia (symptoms plus fingerstick glucose ≤50 mg/dL) occurred in 1 patient in the placebo group.

Conclusions

Addition of saxagliptin 2.5 mg BID to metformin therapy in patients with type 2 diabetes and inadequate glycemic control on metformin monotherapy reduced HbA_1c compared with placebo added to metformin, with an adverse events profile similar to placebo and no unexpected safety findings.

Trial registration

ClinicalTrials.gov NCT00885378

【 授权许可】

   
2014 White et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Zinman B: Initial combination therapy for type 2 diabetes mellitus: is it ready for prime time? Am J Med 2011, 124(1 Suppl):S19-S34.
• [2]Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR: Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care 2012, 35(6):1364-1379.
• [3]Global guideline for type 2 diabetes http://www.staff.ncl.ac.uk/philip.home/IDF%20GGT2D.pdf webcite
• [4]Handelsman Y, Mechanick JI, Blonde L, Grunberger G, Bloomgarden ZT, Bray GA, Dagogo-Jack S, Davidson JA, Einhorn D, Ganda O, Garber AJ, Hirsch IB, Horton ES, Ismail-Beigi F, Jellinger PS, Jones KL, Jovanovič L, Lebovitz H, Levy P, Moghissi ET, Orzeck EA, Vinik AI, Wyne KL: American Association of Clinical Endocrinologists medical guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan. Endocr Pract 2011, 17(2 Suppl):1-53.
• [5]Blonde L, San Juan ZT: Fixed-dose combinations for treatment of type 2 diabetes mellitus. Adv Ther 2012, 29(1):1-13.
• [6]Donnan PT, MacDonald TM, Morris AD: Adherence to prescribed oral hypoglycaemic medication in a population of patients with type 2 diabetes: a retrospective cohort study. Diabet Med 2002, 19(4):279-284.
• [7]Cheong C, Barner JC, Lawson KA, Johnsrud MT: Patient adherence and reimbursement amount for antidiabetic fixed-dose combination products compared with dual therapy among Texas Medicaid recipients. Clin Ther 2008, 30(10):1893-1907.
• [8]Davidson JA: Incorporating incretin-based therapies into clinical practice: differences between glucagon-like peptide 1 receptor agonists and dipeptidyl peptidase 4 inhibitors. Mayo Clin Proc 2010, 85(12 Suppl):S27-S37.
• [9]KOMBIGLYZE XR (saxagliptin and metformin hydrochloride extended-release) tablets http://packageinserts.bms.com/pi/pi_kombiglyze_xr.pdf webcite
• [10]Onglyza® (saxagliptin) tablets http://packageinserts.bms.com/pi/pi_onglyza.pdf webcite
• [11]Onglyza. Summary of product characteristics http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/001039/WC500044316.pdf webcite
• [12]DeFronzo RA, Hissa MN, Garber AJ, Luiz Gross J, Yuyan Duan R, Ravichandran S, Chen RS: The efficacy and safety of saxagliptin when added to metformin therapy in patients with inadequately controlled type 2 diabetes with metformin alone. Diabetes Care 2009, 32(9):1649-1655.
• [13]Hermans MP, Delibasi T, Farmer I, Lohm L, Maheux P, Piatti P, Malvolti E, Jorgens S, Charbonnel B: Effects of saxagliptin added to sub-maximal doses of metformin compared with uptitration of metformin in type 2 diabetes: the PROMPT study. Curr Med Res Opin 2012, 28(10):1635-1645.
• [14]Fonseca V, Zhu T, Karyekar C, Hirshberg B: Adding saxagliptin to extended-release metformin vs. uptitrating metformin dosage. Diabetes Obes Metab 2012, 14(4):365-371.
• [15]Stenlof K, Raz I, Neutel J, Ravichandran S, Berglind N, Chen R: Saxagliptin and metformin XR combination therapy provides glycemic control over 24 hours in patients with T2DM inadequately controlled with metformin. Curr Med Res Opin 2010, 26(10):2355-2363.
• [16]Scheen AJ, Charpentier G, Ostgren CJ, Hellqvist A, Gause-Nilsson I: Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev 2010, 26(7):540-549.
• [17]Göke B, Gallwitz B, Eriksson J, Hellqvist A, Gause-Nilsson I: Saxagliptin is non-inferior to glipizide in patients with type 2 diabetes mellitus inadequately controlled on metformin alone: a 52-week randomised controlled trial. Int J Clin Pract 2010, 64(12):1619-1631.
• [18]Jadzinsky M, Pfutzner A, Paz-Pacheco E, Xu Z, Allen E, Chen R: Saxagliptin given in combination with metformin as initial therapy improves glycaemic control in patients with type 2 diabetes compared with either monotherapy: a randomized controlled trial. Diabetes Obes Metab 2009, 11(6):611-622.
• [19]Pfützner A, Paz-Pacheco E, Allen E, Frederich B, Chen R, for the CV181039 Investigators: Initial combination therapy with saxagliptin and metformin provides sustained glycaemic control and is well tolerated for up to 76 weeks. Diabetes Obes Metab 2011, 13(6):567-576.
• [20]Benford M, Milligan G, Pike J, Anderson P, Piercy J, Fermer S: Fixed-dose combination antidiabetic therapy: real-world factors associated with prescribing choices and relationship with patient satisfaction and compliance. Adv Ther 2012, 29(1):26-40.
• [21]Zhang M, Tsiatis AA, Davidian M: Improving efficiency of inferences in randomized clinical trials using auxiliary covariates. Biometrics 2008, 64(3):707-715.
• [22]Tsiatis AA, Davidian M, Zhang M, Lu X: Covariate adjustment for two-sample treatment comparisons in randomized clinical trials: a principled yet flexible approach. Stat Med 2008, 27(23):4658-4677.
• [23]Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, Hadden D, Turner RC, Holman RR: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000, 321(7258):405-412.
• [24]American Diabetes Association: Standards of medical care in diabetes--2013. Diabetes Care 2013, 36(1 Suppl):S11-S66.
• [25]Chacra AR, Tan GH, Apanovitch A, Ravichandran S, List J, Chen R: Saxagliptin added to a submaximal dose of sulphonylurea improves glycaemic control compared with uptitration of sulphonylurea in patients with type 2 diabetes: a randomised controlled trial. Int J Clin Pract 2009, 63(9):1395-1406.
• [26]Hollander P, Li J, Allen E, Chen R, CV181-013 Investigators: Saxagliptin added to a thiazolidinedione improves glycemic control in patients with type 2 diabetes and inadequate control on thiazolidinedione alone. J Clin Endocrinol Metab 2009, 94(12):4810-4819.
• [27]Cohen RM, Franco RS, Khera PK, Smith EP, Lindsell CJ, Ciraolo PJ, Palascak MB, Joiner CH: Red cell life span heterogeneity in hematologically normal people is sufficient to alter HbA1c. Blood 2008, 112(10):4284-4291.
• [28]Bonora E, Tuomilehto J: The pros and cons of diagnosing diabetes with A1C. Diabetes Care 2011, 34(2 Suppl):S184-S190.
• [29]Freeman JS: Managing hyperglycemia in patients with type 2 diabetes mellitus: rationale for the use of dipeptidyl peptidase-4 inhibitors in combination with other oral antidiabetic drugs. J Am Osteopath Assoc 2010, 110(9):528-537.